A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment.

Trial Profile

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2013

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Glucose intolerance
  • Focus Pharmacodynamics
  • Sponsors Takeda; Takeda Global Research and Development Center; Takeda Pharmaceuticals USA
  • Most Recent Events

    • 20 Sep 2013 Results published in the Journal of Clinical Endocrinology and Metabolism.
    • 26 Jun 2012 Results presented at the 94th Annual Meeting of the Endocrine Society.
    • 02 Feb 2012 Actual end date changed from Jan 2011 to Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top